Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

7.300 +0.220 (+3.11%)
Streaming Delayed Price Updated: 1:24 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. 
Via Benzinga
News headline image
WAVE Life Sciences's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Recap: WAVE Life Sciences Q1 Earnings ↗
 
Via Benzinga
News headline image
Looking Into WAVE Life Sciences's Return On Capital Employed ↗
 
Via Benzinga
News headline image
WAVE Life Sciences's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
News headline image
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Analyst Creates Bullish Pitch For WAVE Life Sciences, Says It Is 'Leader To Clinic In RNA Editing' ↗
Raymond James has initiated coverage on WAVE Life Sciences Ltd (NASDAQ: WVE) with a price target of $9 and  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023 ↗
 
Via Benzinga
News headline image
Analyst Ratings for WAVE Life Sciences ↗
 
Via Benzinga
Looking Into WAVE Life Sciences's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Wave Life Sciences Touts Encouraging Data From Duchenne Muscular Dystrophy Study ↗
 
Via Benzinga
News headline image
Wave Life Sciences' Stock Falls: Investigational Therapy Fails To Show Clinical Benefit In Rare Neurological Diseases ↗
Wave Life Sciences Ltd (NASDAQ: WVE) announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Estee Lauder, NerdWallet, Sprout Social And Other Big Stocks Moving Lower On Wednesday ↗
U.S. stocks mostly traded higher, but the Dow Jones lost around 19 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday. 
Via Benzinga
News headline image
Earnings Scheduled For March 22, 2023 ↗
Companies Reporting Before The Bell • Boyd Gaming (NYSE:BYD) is estimated to report quarterly earnings at $1.09 per share on revenue of $848.27 million. 
Via Benzinga
News headline image
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
20 Favorite Biotech & Medical Stocks For 2023 ↗
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
News headline image
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.